Cimerman N, Prebanda M T, Turk B, Popovic T, Dolenc I, Turk V
Department of Biochemical Research and Drug Design, KRKA, d.d., Ljubljana, Slovenia.
J Enzyme Inhib. 1999;14(2):167-74. doi: 10.3109/14756369909036552.
Recombinant human cystatin C and two of its mutants were expressed in Escherichia coli. The recombinant inhibitor was found to be identical to authentic cystatin C as judged by isoelectric focusing (pI 9.2) and kinetics of inhibition of papain and human cathepsins B, H and L. N-terminal truncation of 8 residues resulted in a decrease of isoelectric point (pI 7.8), but the inhibitory properties were similar to those of recombinant cystatin C, suggesting that Leu9 is a critical residue for the inhibition. The mutation of Trp106 to Ser, however, resulted in a decreased affinity of the inhibitor for the enzymes tested, with the largest effect on cathepsin B inhibition (approximately 100-fold increase in Ki).
重组人胱抑素C及其两个突变体在大肠杆菌中表达。通过等电聚焦(pI 9.2)以及对木瓜蛋白酶和人组织蛋白酶B、H和L的抑制动力学判断,发现重组抑制剂与天然胱抑素C相同。N端截短8个残基导致等电点降低(pI 7.8),但其抑制特性与重组胱抑素C相似,这表明Leu9是抑制作用的关键残基。然而,Trp106突变为Ser导致抑制剂对所测试酶的亲和力降低,对组织蛋白酶B抑制的影响最大(Ki增加约100倍)。